Drugs / DAVAMOTECAN PEGADEXAMER
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02648711 | Oct 2015 → Oct 2017 | cancer | NewLink Genetics Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT01625936 | Jun 2012 → Jul 2017 | renal cell carcinoma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1/23 trials · 1 missed | ||||||
| Phase 1/2 | NCT02389985 | Jul 2015 → Jun 2018 | ovarian cancer | NewLink Genetics Corporation | Terminated | Missed primary |
| Phase 1/2 | NCT02010567 | Dec 2013 → Sep 2016 | rectal cancer | UNC Lineberger Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00333502 | May 2006 → Nov 2011 | cancer | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 27 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT03531827 | Mar 2019 → May 2021 | castration-resistant prostate carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT02187302 | Jul 2014 → Jul 2016 | renal cell carcinoma | NewLink Genetics Corporation | Completed | Missed primary |
| Phase 2 | NCT01803269 | Jan 2013 → Mar 2016 | small cell lung carcinoma | University of Chicago | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01612546 | Nov 2012 → Jan 2015 | diffuse gastric adenocarcinoma, esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric intestinal type adenocarcinoma +1 | City of Hope Medical Center | Completed | Met primary |
| Phase 2 | NCT01652079 | Apr 2012 → Mar 2018 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01380769 | Jun 2011 → Feb 2013 | non-small cell lung carcinoma | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00753740 | Sep 2008 → Oct 2009 | ovarian carcinoma | NewLink Genetics Corporation | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAVAMOTECAN PEGADEXAMER | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802201 ↗ |
| Known as | Cerulean | “CRLX101 (Cerulean)” NCT01625936 ↗ |
| Known as | Crlx-101 drug substance | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802201 ↗ |
| Known as | CRLX101 | “Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors” NCT00333502 ↗ |
| Known as | EP0057 | “EP0057 (formerly CRLX101) is an investigational nanoparticle-drug” PMID 33390325 ↗ Dec 2020 |
| Known as | IT-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00753740 ↗ |
| Known as | NLG207 | “NLG207 (formerly CRLX101) is a nanoparticle-drug conjugate (NDC) of the potent topoisomerase I inhibitor, camptothecin (CPT).” PMID 32897402 ↗ Sep 2020 |
| Action | Inhibit | “cytotoxic topoisomerase-1 inhibitor camptothecin” NCT01612546 ↗ |
| Modality | Other / unclassified | “CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.” NCT00333502 ↗ |
| Route | Intravenous | “when administered intravenously” NCT00333502 ↗ |
| Target | HIF1A | “CRLX101-mediated inhibition of HIF-1α” NCT01652079 ↗ |